PROSTATYPE GENOMICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.039 SEK | +5.41% |
|
-0.50% | -57.89% |
| Sales 2021 | 2.51M 231K | Sales 2022 | 683K 62.92K | Capitalization | 48.46M 4.47M |
|---|---|---|---|---|---|
| Net income 2021 | -15M -1.38M | Net income 2022 | -29M -2.67M | EV / Sales 2021 | 46.2 x |
| Net cash position 2021 | 19.06M 1.76M | Net cash position 2022 | 10.62M 979K | EV / Sales 2022 | 55.4 x |
| P/E ratio 2021 |
-8.09
x | P/E ratio 2022 |
-1.38
x | Employees | 5 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 12.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +8.11% | ||
| 1 week | -0.50% | ||
| Current month | -35.48% | ||
| 1 month | -30.80% | ||
| 3 months | -4.76% | ||
| 6 months | -84.96% | ||
| Current year | -57.89% |
1 week
0.04
0.05
1 month
0.040.07
Current year
0.040.16
1 year
0.040.99
3 years
0.0417.94
5 years
0.0418.40
10 years
0.0418.40
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Persson
CEO | Chief Executive Officer | - | 16-12-31 |
Lars Anders Koch
DFI | Director of Finance/CFO | - | 23-10-30 |
Emelie Berglund
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 12-12-31 | |
| Director/Board Member | 72 | 18-12-31 | |
Michael Häggman
BRD | Director/Board Member | - | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.039 | +5.41% | 40 450 |
| 24-04-24 | 0.037 | -9.31% | 9,065,931 |
| 24-04-23 | 0.0408 | -4.67% | 10,055,630 |
| 24-04-22 | 0.0428 | -3.17% | 4,975,558 |
| 24-04-19 | 0.0442 | +9.95% | 7,578,582 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 03:03 am EDT
More quotes
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Calendar
2024-05-22
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.89% | 3.37M | |
| -16.65% | 8.34B | |
| +39.98% | 3.59B | |
| -32.00% | 2.75B | |
| -7.71% | 2.48B | |
| -9.54% | 2.32B | |
| -13.29% | 1.79B | |
| -19.46% | 1.54B | |
| -40.57% | 1.21B | |
| +9.70% | 1.13B |
- Stock Market
- Equities
- PROGEN Stock
